Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Sexually Transmitted Diseases

  Free Subscription


Articles published in Oral Oncol

Retrieve available abstracts of 66 articles:
HTML format
Text format



Single Articles


    November 2018
  1. PIKE LRG, Hwang WL, Royce TJ, Sanford NN, et al
    HPV status predicts for improved survival following chemotherapy in metastatic squamous cell carcinoma of the oropharynx.
    Oral Oncol. 2018;86:69-74.
    PubMed     Text format     Abstract available


  2. SATHASIVAM HP, Bhatia R, Bradley P, Robson A, et al
    Concurrent HPV-related oropharyngeal carcinoma in four couples.
    Oral Oncol. 2018;86:33-37.
    PubMed     Text format     Abstract available


  3. CANNON RB, Houlton JJ, Patel S, Raju S, et al
    Patterns of cervical node positivity, regional failure rates, and fistula rates for HPV+ oropharyngeal squamous cell carcinoma treated with transoral robotic surgery (TORS).
    Oral Oncol. 2018;86:296-300.
    PubMed     Text format     Abstract available


  4. HUANG SH, Hahn E, Tsang RK, Chen ZJ, et al
    The interplay of IMRT and transoral surgery in HPV-mediated oropharyngeal cancer: Getting the balance right.
    Oral Oncol. 2018;86:171-180.
    PubMed     Text format     Abstract available


  5. SINHA P, Karadaghy OA, Doering MM, Tuuli MG, et al
    Survival for HPV-positive oropharyngeal squamous cell carcinoma with surgical versus non-surgical treatment approach: A systematic review and meta-analysis.
    Oral Oncol. 2018;86:121-131.
    PubMed     Text format     Abstract available


  6. SHAIKH MH, Idris A, Johnson NW, Fallaha S, et al
    Aurora kinases are a novel therapeutic target for HPV-positive head and neck cancers.
    Oral Oncol. 2018;86:105-112.
    PubMed     Text format     Abstract available


    September 2018
  7. GELTZEILER M, Bertolet M, Albergotti W, Gleysteen J, et al
    Staging HPV-related oropharyngeal cancer: Validation of AJCC-8 in a surgical cohort.
    Oral Oncol. 2018;84:82-87.
    PubMed     Text format     Abstract available


    August 2018
  8. LECHNER M, Chakravarthy AR, Walter V, Masterson L, et al
    Frequent HPV-independent p16/INK4A overexpression in head and neck cancer.
    Oral Oncol. 2018;83:32-37.
    PubMed     Text format     Abstract available


  9. GRONHOJ C, Jakobsen KK, Jensen DH, Rasmussen J, et al
    Pattern of and survival following loco-regional and distant recurrence in patients with HPV+ and HPV- oropharyngeal squamous cell carcinoma: A population-based study.
    Oral Oncol. 2018;83:127-133.
    PubMed     Text format     Abstract available


    July 2018
  10. PASALIC D, Funk RK, Garcia JJ, Price DL, et al
    Magnitude of benefit for adjuvant radiotherapy following minimally invasive surgery in intermediate to high risk HPV-positive oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2018;82:181-186.
    PubMed     Text format     Abstract available


  11. HOBELMANN KC, Topf MC, Bar-Ad V, Luginbuhl AJ, et al
    AJCC-8ed nodal staging does not predict outcomes in surgically managed HPV-associated oropharyngeal cancer.
    Oral Oncol. 2018;82:138-143.
    PubMed     Text format     Abstract available


  12. MIRGHANI H, Leroy C, Chekourry Y, Casiraghi O, et al
    Smoking impact on HPV driven head and neck cancer's oncological outcomes?
    Oral Oncol. 2018;82:131-137.
    PubMed     Text format     Abstract available


  13. MIRGHANI H, Lang Kuhs KA, Waterboer T
    Biomarkers for early identification of recurrences in HPV-driven oropharyngeal cancer.
    Oral Oncol. 2018;82:108-114.
    PubMed     Text format     Abstract available


    April 2018
  14. VANGELOV B, Kotevski DP, Williams JR, Smee RI, et al
    The impact of HPV status on weight loss and feeding tube use in oropharyngeal carcinoma.
    Oral Oncol. 2018;79:33-39.
    PubMed     Text format     Abstract available


    March 2018
  15. GOUW ZAR, Paul de Boer J, Navran A, van den Brekel MWM, et al
    Baseline peripheral blood leukocytosis: Biological marker predicts outcome in oropharyngeal cancer, regardless of HPV-status.
    Oral Oncol. 2018;78:200-206.
    PubMed     Text format     Abstract available


  16. LU S, Concha-Benavente F, Shayan G, Srivastava RM, et al
    STING activation enhances cetuximab-mediated NK cell activation and DC maturation and correlates with HPV(+) status in head and neck cancer.
    Oral Oncol. 2018;78:186-193.
    PubMed     Text format     Abstract available


  17. CHANNIR HI, Kiss K, Rubek N, Andersen J, et al
    Comparison of clinical, radiological and morphological features including the distribution of HPV E6/E7 oncogenes in resection specimens of oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2018;78:163-170.
    PubMed     Text format     Abstract available


  18. MENA M, Taberna M, Tous S, Marquez S, et al
    Double positivity for HPV-DNA/p16(ink4a) is the biomarker with strongest diagnostic accuracy and prognostic value for human papillomavirus related oropharyngeal cancer patients.
    Oral Oncol. 2018;78:137-144.
    PubMed     Text format     Abstract available


  19. WANG K, Wong TZ, Amdur RJ, Mendenhall WM, et al
    Pitfalls of post-treatment PET after de-intensified chemoradiotherapy for HPV-associated oropharynx cancer: Secondary analysis of a phase 2 trial.
    Oral Oncol. 2018;78:108-113.
    PubMed     Text format     Abstract available


    February 2018
  20. GIPSON BJ, Robbins HA, Fakhry C, D'Souza G, et al
    Sensitivity and specificity of oral HPV detection for HPV-positive head and neck cancer.
    Oral Oncol. 2018;77:52-56.
    PubMed     Text format     Abstract available


  21. MAJERCAKOVA K, Valero C, Lopez M, Garcia J, et al
    Postoperative staging of the neck dissection using extracapsular spread and lymph node ratio as prognostic factors in HPV-negative head and neck squamous cell carcinoma patients.
    Oral Oncol. 2018;77:37-42.
    PubMed     Text format     Abstract available


    January 2018
  22. JANSEN L, Buttmann-Schweiger N, Listl S, Ressing M, et al
    Differences in incidence and survival of oral cavity and pharyngeal cancers between Germany and the United States depend on the HPV-association of the cancer site.
    Oral Oncol. 2018;76:8-15.
    PubMed     Text format     Abstract available


    October 2017
  23. UPADHYAY P, Gardi N, Desai S, Chandrani P, et al
    Genomic characterization of tobacco/nut chewing HPV-negative early stage tongue tumors identify MMP10 asa candidate to predict metastases.
    Oral Oncol. 2017;73:56-64.
    PubMed     Text format     Abstract available


  24. SHARMA SJ, Wittekindt C, Knuth J, Steiner D, et al
    Intraindividual homogeneity of 18F-FDG PET/CT parameters in HPV-positive OPSCC.
    Oral Oncol. 2017;73:166-171.
    PubMed     Text format     Abstract available


  25. ZHAN KY, Eskander A, Kang SY, Old MO, et al
    Appraisal of the AJCC 8th edition pathologic staging modifications for HPV-positive oropharyngeal cancer, a study of the National Cancer Data Base.
    Oral Oncol. 2017;73:152-159.
    PubMed     Text format     Abstract available


    September 2017
  26. DONA MG, Rollo F, Pichi B, Spriano G, et al
    Evaluation of the Xpert(R) HPV assay in the detection of Human Papillomavirus in formalin-fixed paraffin-embedded oropharyngeal carcinomas.
    Oral Oncol. 2017;72:117-122.
    PubMed     Text format     Abstract available


  27. ADKINS D, Ley J, Oppelt P, Wildes TM, et al
    nab-Paclitaxel-based induction chemotherapy with or without cetuximab for locally advanced head and neck squamous cell carcinoma.
    Oral Oncol. 2017;72:26-31.
    PubMed     Text format     Abstract available


    August 2017
  28. OU D, Blanchard P, Rosellini S, Levy A, et al
    Predictive and prognostic value of CT based radiomics signature in locally advanced head and neck cancers patients treated with concurrent chemoradiotherapy or bioradiotherapy and its added value to Human Papillomavirus status.
    Oral Oncol. 2017;71:150-155.
    PubMed     Text format     Abstract available


    July 2017
  29. BROGLIE MA, Jochum W, Michel A, Waterboer T, et al
    Evaluation of type-specific antibodies to high risk-human papillomavirus (HPV) proteins in patients with oropharyngeal cancer.
    Oral Oncol. 2017;70:43-50.
    PubMed     Text format     Abstract available


    June 2017
  30. DABAS S, Gupta K, Ranjan R, Sharma AK, et al
    Oncological outcome following de-intensification of treatment for stage I and II HPV negative oropharyngeal cancers with transoral robotic surgery (TORS): A prospective trial.
    Oral Oncol. 2017;69:80-83.
    PubMed     Text format     Abstract available


  31. LAPRISE C, Madathil SA, Schlecht NF, Castonguay G, et al
    Human papillomavirus genotypes and risk of head and neck cancers: Results from the HeNCe Life case-control study.
    Oral Oncol. 2017;69:56-61.
    PubMed     Text format     Abstract available


    May 2017
  32. DODD RH, Forster AS, Waller J, Marlow LAV, et al
    Discussing HPV with oropharyngeal cancer patients: A cross-sectional survey of attitudes in health professionals.
    Oral Oncol. 2017;68:67-73.
    PubMed     Text format     Abstract available


  33. SHAIKH MH, Clarke DTW, Johnson NW, McMillan NAJ, et al
    Can gene editing and silencing technologies play a role in the treatment of head and neck cancer?
    Oral Oncol. 2017;68:9-19.
    PubMed     Text format     Abstract available


    April 2017
  34. ZHANG Y, Waterboer T, Haddad RI, Miles BA, et al
    Human papillomavirus (HPV) 16 antibodies at diagnosis of HPV-related oropharyngeal cancer and antibody trajectories after treatment.
    Oral Oncol. 2017;67:77-82.
    PubMed     Text format     Abstract available


  35. LACAU ST GUILY J, Rousseau A, Baujat B, Perie S, et al
    Oropharyngeal cancer prognosis by tumour HPV status in France: The multicentric Papillophar study.
    Oral Oncol. 2017;67:29-36.
    PubMed     Text format     Abstract available


  36. PEREZ CA, Wu X, Amsbaugh MJ, Gosain R, et al
    High-dose versus weekly cisplatin definitive chemoradiotherapy for HPV-related oropharyngeal squamous cell carcinoma of the head and neck.
    Oral Oncol. 2017;67:24-28.
    PubMed     Text format     Abstract available


  37. MIRGHANI H, Sturgis EM, Auperin A, Monsonego J, et al
    Is there an increased risk of cancer among spouses of patients with an HPV-related cancer: A systematic review.
    Oral Oncol. 2017;67:138-145.
    PubMed     Text format     Abstract available


  38. TOTA JE, Anderson WF, Coffey C, Califano J, et al
    Rising incidence of oral tongue cancer among white men and women in the United States, 1973-2012.
    Oral Oncol. 2017;67:146-152.
    PubMed     Text format     Abstract available


  39. KOFLER B, Borena W, Manzl C, Dudas J, et al
    Sensitivity of tumor surface brushings to detect human papilloma virus DNA in head and neck cancer.
    Oral Oncol. 2017;67:103-108.
    PubMed     Text format     Abstract available


    March 2017
  40. PORCEDDU SV, Milne R, Brown E, Bernard A, et al
    Validation of the ICON-S staging for HPV-associated oropharyngeal carcinoma using a pre-defined treatment policy.
    Oral Oncol. 2017;66:81-86.
    PubMed     Text format     Abstract available


    February 2017
  41. GELTZEILER M, Clayburgh D, Gleysteen J, Gross ND, et al
    Predictors of extracapsular extension in HPV-associated oropharyngeal cancer treated surgically.
    Oral Oncol. 2017;65:89-93.
    PubMed     Text format     Abstract available


  42. MASSA ST, Osazuwa-Peters N, Christopher KM, Arnold LD, et al
    Competing causes of death in the head and neck cancer population.
    Oral Oncol. 2017;65:8-15.
    PubMed     Text format     Abstract available


    January 2017
  43. MARTEL M, Alemany L, Taberna M, Mena M, et al
    The role of HPV on the risk of second primary neoplasia in patients with oropharyngeal carcinoma.
    Oral Oncol. 2017;64:37-43.
    PubMed     Text format     Abstract available


    December 2016
  44. D'SOUZA G, Anantharaman D, Gheit T, Abedi-Ardekani B, et al
    Corrigendum to 'Effect of HPV on head and neck cancer patient survival, by region and tumor site: A comparison of 1362 cases across three continents' [Oral Oncol. 62 (2016) 20-27].
    Oral Oncol. 2016 Dec 30. pii: S1368-8375(16)30270.
    PubMed     Text format    


  45. JEANNON JP, Tanaka A, Thavaraj S, Guerrero-Urbano T, et al
    ATR gene mutations in HPV negative oropharyngeal cancer.
    Oral Oncol. 2016 Dec 22. pii: S1368-8375(16)30244.
    PubMed     Text format    


  46. CHERA B, Wang K, Monroe A, Galloway T, et al
    Truth or myth: Definitive chemoradiotherapy doesn't work for HPV/p16 negative oropharyngeal squamous cell carcinoma?
    Oral Oncol. 2016 Dec 16. pii: S1368-8375(16)30234.
    PubMed     Text format    


  47. INGLEHART RC, Taberna M, Pickard RK, Hoff M, et al
    HPV knowledge gaps and information seeking by oral cancer patients.
    Oral Oncol. 2016;63:23-29.
    PubMed     Text format     Abstract available


  48. FERNANDEZ-MATEOS J, Seijas-Tamayo R, Mesia R, Taberna M, et al
    Epidermal growth factor receptor (EGFR) pathway polymorphisms as predictive markers of cetuximab toxicity in locally advanced head and neck squamous cell carcinoma (HNSCC) in a Spanish population.
    Oral Oncol. 2016;63:38-43.
    PubMed     Text format     Abstract available


    November 2016
  49. D'SOUZA G, Anantharaman D, Gheit T, Abedi-Ardekani B, et al
    Effect of HPV on head and neck cancer patient survival, by region and tumor site: A comparison of 1362 cases across three continents.
    Oral Oncol. 2016;62:20-27.
    PubMed     Text format     Abstract available


  50. HAUGHEY BH, Sinha P, Kallogjeri D, Goldberg RL, et al
    Pathology-based staging for HPV-positive squamous carcinoma of the oropharynx.
    Oral Oncol. 2016;62:11-19.
    PubMed     Text format     Abstract available


  51. MIRGHANI H, Casiraghi O, Guerlain J, Amen F, et al
    Diagnosis of HPV driven oropharyngeal cancers: Comparing p16 based algorithms with the RNAscope HPV-test.
    Oral Oncol. 2016;62:101-108.
    PubMed     Text format     Abstract available


  52. KINDT N, Descamps G, Seminerio I, Bellier J, et al
    Langerhans cell number is a strong and independent prognostic factor for head and neck squamous cell carcinomas.
    Oral Oncol. 2016;62:1-10.
    PubMed     Text format     Abstract available


    October 2016
  53. WIRTH LJ, Dakhil S, Kornek G, Axelrod R, et al
    PARTNER: An open-label, randomized, phase 2 study of docetaxel/cisplatin chemotherapy with or without panitumumab as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck.
    Oral Oncol. 2016;61:31-40.
    PubMed     Text format     Abstract available


  54. LOW GM, Thylur DS, N Yamamoto V, Sinha UK, et al
    The effect of human papillomavirus on DNA repair in head and neck squamous cell carcinoma.
    Oral Oncol. 2016;61:27-30.
    PubMed     Text format     Abstract available


    August 2016
  55. OU D, Levy A, Blanchard P, Nguyen F, et al
    Concurrent chemoradiotherapy with cisplatin or cetuximab for locally advanced head and neck squamous cell carcinomas: Does human papilloma virus play a role?
    Oral Oncol. 2016;59:50-7.
    PubMed     Text format     Abstract available


    July 2016
  56. WANG K, Amdur RJ, Mendenhall WM, Green R, et al
    Impact of post-chemoradiotherapy superselective/selective neck dissection on patient reported quality of life.
    Oral Oncol. 2016;58:21-6.
    PubMed     Text format     Abstract available


    May 2016
  57. FENG Y, Li Y, Zhang Y, Zheng H, et al
    Association of genetic variants with tumor HPV16 status and survival in squamous cell carcinoma of the oropharynx.
    Oral Oncol. 2016;56:78-83.
    PubMed     Text format     Abstract available


  58. ZAFEREO ME, Xu L, Dahlstrom KR, Viamonte CA, et al
    Squamous cell carcinoma of the oral cavity often overexpresses p16 but is rarely driven by human papillomavirus.
    Oral Oncol. 2016;56:47-53.
    PubMed     Text format     Abstract available


  59. LAROCCA CJ, Han J, Salzwedel AO, Davydova J, et al
    Oncolytic adenoviruses targeted to Human Papilloma Virus-positive head and neck squamous cell carcinomas.
    Oral Oncol. 2016;56:25-31.
    PubMed     Text format     Abstract available


  60. AMINI A, Jasem J, Jones BL, Robin TP, et al
    Predictors of overall survival in human papillomavirus-associated oropharyngeal cancer using the National Cancer Data Base.
    Oral Oncol. 2016;56:1-7.
    PubMed     Text format     Abstract available


    April 2016
  61. KANG H, Kwon M, Park JJ, Kim JP, et al
    Clinical implications of human papilloma virus and other biologic markers in nasopharyngeal cancer.
    Oral Oncol. 2016;55:e7-e10.
    PubMed     Text format    


    March 2016
  62. SEDGHIZADEH PP, Billington WD, Paxton D, Ebeed R, et al
    Is p16-positive oropharyngeal squamous cell carcinoma associated with favorable prognosis? A systematic review and meta-analysis.
    Oral Oncol. 2016;54:15-27.
    PubMed     Text format     Abstract available


  63. SHER DJ, Schwartz DL, Nedzi L, Khan S, et al
    Comparative effectiveness of induction chemotherapy for oropharyngeal squamous cell carcinoma: A population-based analysis.
    Oral Oncol. 2016;54:58-67.
    PubMed     Text format     Abstract available


  64. OZRETIC L, Wagner S, Huebbers CU, Gattenlohner S, et al
    FGFR1 amplification and co-overexpression of c-MYC in oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2016;54:e7-9.
    PubMed     Text format    


    January 2016
  65. MAZUREK AM, Rutkowski T, Fiszer-Kierzkowska A, Malusecka E, et al
    Assessment of the total cfDNA and HPV16/18 detection in plasma samples of head and neck squamous cell carcinoma patients.
    Oral Oncol. 2016 Jan 11. pii: S1368-8375(15)00428.
    PubMed     Text format     Abstract available


  66. GUO T, Rettig E, Fakhry C
    Understanding the impact of survival and human papillomavirus tumor status on timing of recurrence in oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2016;52:97-103.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Sexually Transmitted Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: